Predict your next investment

Verana Health company logo
Corporation
INTERNET | Internet Software & Services / Healthcare
veranahealth.com

See what CB Insights has to offer


Founded Year

2017

Stage

Series D | Alive

Total Raised

$137.8M

Last Raised

$100M | 1 yr ago

About Verana Health

Verana Health, formerly known as DigiSight Technologies, assembles clinical databases in medicine to empower physicians and accelerate research for patients.

Verana Health Headquarter Location

600 Harrison Street #250

San Francisco, California, 94107,

United States

650-223-5560

Latest Verana Health News

08:55 ET Steep Decline in Prostate Cancer Outpatient Visits During the COVID-19 Pandemic, According to Research by Verana Health...

Jun 4, 2021

Findings of AQUA Registry real-world data analysis to be presented during annual meeting of the American Society of Clinical Oncology News provided by Share this article Share this article SAN FRANCISCO, June 4, 2021 /PRNewswire/ -- Verana Health —a healthcare technology and analytics innovator focused on transforming multi-specialty clinical data into real-world evidence—and the American Urological Association (AUA) today unveiled findings of a research collaboration showing that the COVID-19 pandemic sharply curtailed access to outpatient care for men with prostate cancer in the United States across all risk groups, but particularly for those with low-risk disease. Prostate cancer is one of the leading causes of death in older men. Findings of the study are being presented by Matt Cooperberg, MD, MPH, professor of urology and epidemiology & biostatistics at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, at the annual meeting of the American Society of Clinical Oncology (ASCO) from June 4-8. Dr. Cooperberg is the lead author and will present via video recording at the meeting. The study's goal was to document national, real-world trends in prostate cancer diagnoses and treatment throughout the throes of the pandemic during 2020, using data from the AUA Quality Registry ( AQUA ), a national Qualified Clinical Data Registry (QCDR) designed to measure, report, and improve healthcare quality and patient outcomes. While evaluations of prostate cancer management to date have been limited largely to specific healthcare systems and geographic regions, 158 urology practices across the U.S. contributed data from their practices' electronic health records (EHRs) to the study through their participation in the AQUA registry. Researchers looked at visits for prostate cancer, use of diagnostic procedures such as prostate biopsies, and prostate cancer treatments including surgical prostatectomy and radiation administration across different patient risk categories. "Mean daily prostate cancer visits per urology practice declined sharply among all risk categories, but the steepest drop was for visits for low-risk prostate cancer, which were down nearly 50% from the previous year. Though there was a recovery after the initial drop, visit volume fell even further through the second half of 2020," said Dr. Cooperberg. "Further studies will thus be needed to assess the downstream consequences of delayed evaluation and management for men with prostate cancer." The large decline in visits for early-stage prostate cancer patients started in March 2020 and was followed by an initial recovery in visit volumes after several months. However, a secondary decline in visits—preceding and worsening during the pandemic surge in the fall of 2020—led to lower visit volumes across all patient risk categories by year's end compared with the first drop in visit volumes initially observed. Both the steepness of the initial decline in visits and pace of recovery varied by race, geography, and other factors. In addition to documenting the impact of the pandemic on prostate cancer visits and treatments, the research underscores the value of analyzing real-world healthcare data to track changes in care as they unfold. Most of the real-world data regarding early-stage prostate cancer—as well as other genitourinary cancers including bladder and upper tract urothelial cancer, renal cell carcinoma, and testicular cancer—are generated by urologists, given that the diagnostic procedures and initial treatments are usually performed by urologists. In contrast, oncologists typically become involved in the care of patients with genitourinary cancers when the disease is advanced and/or metastatic, often well after treatment strategies have been initiated and directed by urologists. As such, the real-world EHR data from urology practices participating in the AQUA registry are unique for characterizing and describing the disease trajectories for genitourinary cancers. "The data on early-stage genitourinary cancers in the AQUA registry are invaluable to researchers and clinicians," said Matthew Roe, MD, MHS, chief medical officer at Verana Health and a co-author of the study. "By partnering with AUA to apply our data curation and analytics capabilities to the AQUA registry, Verana Health is helping the organization fulfill its mission of improving care for patients with urological disorders." The AUA promotes the highest standards of urological clinical care through research like the partnership with Verana Health. Continued research through the AQUA registry will also result in further insights into the effectiveness of treatments for early-stage genitourinary cancers. "For urologists and genitourinary cancer patients, early detection and treatment are critical to successful outcomes," said David F. Penson, MD, MPH, AUA Science and Quality Council Chair. "Thanks to our collaboration with Verana Health, we now have a better understanding about changes in care due to the COVID-19 pandemic that we can study to gauge the long-term impact of delayed diagnoses and treatments for prostate cancer." For more information, view the study abstract here . About Verana Health Verana Health is a healthcare technology and analytics company entrusted by key medical associations to manage multi-specialty, real-world data at every stage of the analytics process—from entry to evidence. Anchored in ophthalmology, neurology, and urology, the Company acts as a linchpin in the healthcare data ecosystem, making data meaningful and actionable to empower physicians and accelerate research for patients. By curating and applying advanced analytics to real-world clinical data, Verana Health helps life sciences partners enhance evidence generation, reinvent medical research, and drive innovations in specific disease areas. For more information on Verana Health, visit  www.veranahealth.com . About the American Urological Association Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association (AUA) is a leading advocate for the specialty of urology and has nearly 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. For more information on AUA, visit https://www.auanet.org . Media Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Verana Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Verana Health in 2 CB Insights research briefs, most recently on Sep 2, 2020.

Expert Collections containing Verana Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verana Health is included in 6 Expert Collections, including Clinical Trials Tech.

C

Clinical Trials Tech

424 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

E

Eye Health

711 items

b

big data

1,068 items

G

GE Ventures Healthcare Portfolio

21 items

D

Digital Health 150 (2019)

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

I

Infectious Disease

2,270 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Verana Health Patents

Verana Health has filed 4 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Ophthalmology
  • Astronomical imaging
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/17/2016

1/29/2019

Adapter for retinal imaging using a hand held computer

Ophthalmology, Diseases of the eye and adnexa, Photography equipment, Medical equipment, Geometrical optics

Grant

3/1/2010

10/26/1991

Subscribe to see more

Subscribe to see more

Subscribe to see more

1/1/2015

1/2/1983

Subscribe to see more

Subscribe to see more

Subscribe to see more

10/6/2014

6/11/2015

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/17/2016

5/14/1953

1/11/1986

11/11/1995

Grant Date

1/29/2019

11/9/2015

3/30/1984

4/3/2013

Title

Adapter for retinal imaging using a hand held computer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Ophthalmology, Diseases of the eye and adnexa, Photography equipment, Medical equipment, Geometrical optics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Verana Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verana Health Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.